Hepatitis B virus infection in dialysis patients

摘要: Hepatitis B virus (HBV) infection remains a major issue among dialysis patients. It is associated with high risk of hepatic complication. The liver disease runs unique clinical course in patients, as it can progress modest inflammation and prominent fibrosis. conventional cut-off level serum alanine aminotransferase (ALT) for commencing antiviral therapy may prove too inappropriate biopsy appears to be the only definitive means establish activity Liver should considered patients ALT that persistently greater than 30 IU/L, or 0.75-fold upper limit normal level, and/or other laboratory findings suggest active disease. For treatment, preliminary reports have shown lamivudine effective well tolerated However, long-term efficacy its optimal dose remain unknown. prevention nosocomial transmission also important. Universal precaution measures strictly observed segregation hepatitis surface antigen-positive hemodialysis considered. HBV non-immune importance vaccination not overemphasized. Until new generation highly immunogenic vaccines are proven safe end-stage renal becomes available, early before development failure best way secure immunological protection against